{
  "id": 8306255,
  "title": "Teva Announces New Olanzapine LAI (TEV-‘749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults",
  "url": "https://urgent.news/2026/09/18/teva-announces-new-olanzapine-lai-tev-749-post-hoc-data-highlighting",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T20:32:00.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/teva-announces-new-olanzapine-lai-tev-749-post-hoc-data-highlighting-high-rates-of-stabilization-and-long-term-efficacy-as-once-monthly-subcutaneous-injectable-for-the-treatment-of-schizophrenia-i"
  },
  "original_language": "en",
  "account": null,
  "summary": "In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-‘749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-‘749 for ≥ 6 months met criteria for remission Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}